Dr. Matthew F. Buas is an Assistant Professor of Oncology in the Department of Cancer Prevention and Control, and joined the Roswell Park faculty in 2016. He earned a PhD in Cell and Molecular Biology from the University of Pennsylvania, an MS in Epidemiology from the University of Washington, and conducted post-doctoral research in cancer epidemiology at the Fred Hutchinson Cancer Research Center.
Dr. Buas’ primary research focus is the molecular/genetic epidemiology of esophageal adenocarcinoma (EA), and the development of novel approaches for cancer risk assessment, early diagnosis, and prevention. His active research includes basic etiologic studies of genetic susceptibility to EA and its precursor, Barrett’s esophagus (BE); applied biomarker discovery studies of circulating nucleic acids and metabolites linked to high-risk BE and early-stage EA; and integrative risk modeling studies aimed at combining genetic and non-genetic factors into robust predictors of absolute cancer risk. The long-term translational goal of this work is to synthesize improved clinical tools for enabling targeted prevention or timely interception of EA among at-risk individuals.
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Carlton House A369
Buffalo, NY 14263
Dai JY, Wang X, Buas MF, Zhang C, Ma J, Wei B, Li Y, et al. (2018) Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun Biol. 1:174.
Buas MF, Gu H, Djukovic D, Zhu J, Reid BJ, Raftery D, Vaughan TL. (2017) Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett’s esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics, 13: 23.
Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, et al. (2017) Determining risk of Barrett’s esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. Gastroenterology, 154(5):1273-1281.
Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, et al. (2016) Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut, 66, 1739-1747.
Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, et al. (2016) Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol., 17, 1363-1373.
Dai JY, Tapsoba Jde D, Buas MF; BEACON Consortium, Risch HA, Vaughan TL. (2016) Constrained Score Statistics Identify Genetic Variants Interacting with Multiple Risk Factors in Barrett's Esophagus. Am J Hum Genet., 99, 352-65.
Buas MF, Gu H, Djukovic D, Zhu J, Urban N, Raftery D, Li CI. (2016) Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol., 140, 138-44.
Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, et al. (2014) Integrative post-GWAS analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis, 35, 2740-7.